Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OCRELIZUMAB vs OFATUMUMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OCRELIZUMAB vs OFATUMUMAB: Safety Overview

Metric OCRELIZUMAB OFATUMUMAB
Total FAERS Reports 56,186 29,913
Deaths Reported 1,406 695
Death Rate 2.5% 2.3%
Hospitalizations 10,364 3,616
Average Patient Age 47.2 yrs 47.5 yrs
% Female Patients 72.5% 74.9%
Manufacturer Genentech, Inc. Novartis Pharmaceuticals Corporation
Route INTRAVENOUS INTRAVENOUS
Marketing Status Prescription Prescription